Edition:
United States

Strongbridge Biopharma plc (SBBP.OQ)

SBBP.OQ on NASDAQ Stock Exchange Global Select Market

6.80USD
16 Feb 2018
Change (% chg)

$0.05 (+0.74%)
Prev Close
$6.75
Open
$6.70
Day's High
$6.90
Day's Low
$6.70
Volume
33,815
Avg. Vol
65,710
52-wk High
$9.02
52-wk Low
$2.45

Chart for

About

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of... (more)

Overall

Beta: --
Market Cap(Mil.): $307.07
Shares Outstanding(Mil.): 45.16
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 32.03 17.27
EPS (TTM): -- -- --
ROI: -- 14.00 35.43
ROE: -- 15.34 17.10

BRIEF-Strongbridge Biopharma Announces Pricing Of Public Offering

* STRONGBRIDGE BIOPHARMA PLC ANNOUNCES PRICING OF PUBLIC OFFERING OF ORDINARY SHARES

Jan 25 2018

BRIEF-Strongbridge Biopharma Announces Proposed Public Offering Of 5 Mln Ordinary Shares

* STRONGBRIDGE BIOPHARMA PLC ANNOUNCES PROPOSED PUBLIC OFFERING OF 5 MILLION ORDINARY SHARES Source text for Eikon: Further company coverage:

Jan 23 2018

BRIEF-Strongbridge Biopharma Receives Notice Of Allowance From U.S. Patent And Trademark Office For New Patent Covering RECORLEV

* STRONGBRIDGE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FROM U.S. PATENT AND TRADEMARK OFFICE FOR NEW PATENT COVERING RECORLEV™ (LEVOKETOCONAZOLE) FOR THE TREATMENT OF CUSHING’S SYNDROME

Jan 18 2018

BRIEF-Strongbridge Announces Acquisition Of U.S., Canadian Rights To Macrilen From Aeterna Zentaris

* STRONGBRIDGE BIOPHARMA PLC ANNOUNCES ACQUISITION OF THE U.S. AND CANADIAN RIGHTS TO MACRILEN™ (MACIMORELIN) FROM AETERNA ZENTARIS

Jan 17 2018

BRIEF-Aeterna Zentaris Enters Licensing Agreement With Strongbridge For Macrilen In U.S., Canada

* AETERNA ZENTARIS ENTERS INTO LICENSING AND ASSIGNMENT AGREEMENT WITH STRONGBRIDGE FOR MACRILEN™ (MACIMORELIN) IN THE U.S. AND CANADA

Jan 17 2018

BRIEF-Strongbridge Gets Letters From Offices Of U.S. Senators Requesting Information On Marketing & Sales Of Keveyis

* STRONGBRIDGE BIOPHARMA - ON DEC 19, RECEIVED LETTERS FROM OFFICES OF U.S. SENATORS THAT REQUEST INFORMATION RELATING TO MARKETING & SALES OF KEVEYIS

Dec 21 2017

BRIEF-Strongbridge Biopharma Q3 loss per share $0.98

* Strongbridge Biopharma Plc provides corporate update and reports third quarter 2017 financial results

Nov 14 2017

BRIEF-Strongbridge Biopharma Plc announces proposed public offering of ordinary shares

* Strongbridge Biopharma Plc announces proposed public offering of ordinary shares

Oct 03 2017

BRIEF-Armistice Capital Llc reports 5.1 percent passive stake in Strongbridge Biopharma

* Armistice Capital Llc reports 5.1 percent passive stake in Strongbridge Biopharma Plc as of Sept 12, 2017 - SEC filing Source text: (http://bit.ly/2xlELBz) Further company coverage:

Sep 22 2017

Earnings vs. Estimates